Description: Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Home Page: www.paradigmbiopharma.com
500 Collins Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9629 5566
Officers
| Name | Title |
|---|---|
| Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC | Founder, MD & Exec. Chairman |
| Dr. Donna L. Skerrett M.D., MS | Chief Medical Officer and Exec. Director |
| Mr. Justin Cahill | Chief Financial Officer |
| Dr. Ravi Krishnan | Chief Scientific Officer |
| Mr. Simon White | Director of Investor Relations |
| Dr. Michael Imperiale | Global Head of Drug Safety & MPS |
| Ms. Beverley Huttmann | Commercial Head |
| Ms. Michelle Coffey | Global Head of Regulatory Affairs |
| Dr. Mukesh Ahuja | Global Clinical Head of OA |
| Mr. Marco Polizzi | Exec. Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.7575 |
| Price-to-Sales TTM: | 3287.0374 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |